Inspire Medical Systems (NYSE:INSP – Get Free Report) had its price objective decreased by research analysts at Truist Financial from $64.00 to $50.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s price objective indicates a potential upside of 8.37% from the stock’s current price.
Other equities research analysts also recently issued reports about the stock. UBS Group set a $67.00 price target on shares of Inspire Medical Systems in a report on Friday, February 13th. Royal Bank Of Canada restated a “sector perform” rating and set a $56.00 price objective on shares of Inspire Medical Systems in a report on Tuesday, April 14th. Morgan Stanley set a $60.00 price objective on Inspire Medical Systems in a report on Wednesday, February 18th. Robert W. Baird dropped their target price on Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating on the stock in a report on Tuesday. Finally, Oppenheimer downgraded Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $93.33.
View Our Latest Stock Analysis on INSP
Inspire Medical Systems Trading Down 15.9%
Inspire Medical Systems (NYSE:INSP – Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.38. The business had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities analysts predict that Inspire Medical Systems will post 1.82 EPS for the current year.
Institutional Investors Weigh In On Inspire Medical Systems
Several hedge funds have recently modified their holdings of the business. Wellington Management Group LLP bought a new stake in shares of Inspire Medical Systems in the fourth quarter valued at approximately $203,929,000. Wasatch Advisors LP boosted its position in shares of Inspire Medical Systems by 7.2% in the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after acquiring an additional 110,288 shares during the period. William Blair Investment Management LLC raised its stake in shares of Inspire Medical Systems by 68.7% in the third quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock valued at $96,280,000 after purchasing an additional 528,404 shares in the last quarter. Morgan Stanley raised its stake in shares of Inspire Medical Systems by 179.5% in the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after purchasing an additional 809,121 shares in the last quarter. Finally, Deerfield Management Company L.P. raised its stake in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares in the last quarter. 94.91% of the stock is owned by institutional investors.
Inspire Medical Systems News Summary
Here are the key news stories impacting Inspire Medical Systems this week:
- Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS (vs. consensus loss) and $204.6M revenue, topping Street expectations and showing modest year-over-year sales growth. This supports the company’s underlying business strength. GlobeNewswire: Q1 Results
- Neutral Sentiment: Analyst note: Mizuho cut its price target from $70 to $55 but kept an “outperform” rating — the new target offers almost no upside versus the current price, so it is mixed (still favorable rating but lower conviction on upside). Benzinga
- Neutral Sentiment: Company materials and call transcript are available for investors reviewing management commentary and the details behind the guidance change. Earnings Call Summary (Yahoo)
- Negative Sentiment: Guidance cut — Inspire narrowed FY2026 EPS guidance to $0.75–$1.25 (street ~$1.99) and revenue to $825M–$875M (street ~$961M). Management cited reimbursement/coding issues and WISeR disruption as drivers of the downgrade, which materially reduces expected growth and margins. Seeking Alpha: Guidance & WISeR Disruption
- Negative Sentiment: Analyst downgrades/price-target cuts — Robert W. Baird cut its target to $50 and moved to “neutral”; Bank of America reaffirmed “neutral” with a $53 target. Those moves signal reduced analyst confidence and put further pressure on the shares. The Fly: Baird Note
- Negative Sentiment: Market reaction: coverage and headlines emphasizing the guidance cut and reimbursement uncertainty drove a sharp intraday sell-off (coverage noted a large single-day decline following the update). Yahoo Finance: Stock Reaction
About Inspire Medical Systems
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
Read More
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
